Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial
CONCLUSIONS: Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.PMID:34667023 | DOI:10.1158/1078-0432.CCR-21-2260
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Maria Vittoria Dieci Valentina Guarneri Anna Tosi Giancarlo Bisagni Antonino Musolino Simon Spazzapan Gabriella Moretti Grazia Maria Vernaci Gaia Griguolo Tommaso Giarratano Loredana Urso Francesca Schiavi Claudia Pinato Giovanna Magni Marcello Lo Mele Gi Source Type: research
More News: Addison's Disease | Adrenal Insufficiency | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | HER2 | Hormones | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy